Janssen pharmaceuticals. Janssen-silag. See what "Janssen Pharmaceutica" is in other dictionaries

Janssen Pharmaceuticals

Janssen-Cilag was formed from the merger of two pharmaceutical companies, each of which has a long tradition: the Belgian Janssen Pharmaceutica and the Swiss Cilag.

Janssen Pharmaceuticals was founded in Belgium in 1992 by a young doctor, Paul Janssen. However, the history of the company began with Paul Janssen's father, Dr. Konstantas Janssen, who founded a small pharmaceutical company in the year that was engaged in the import and distribution of medical preparations. Everything changed with the arrival of his son, Dr. Paul Janssen, who, having received medical education, was fond of chemistry and pharmacology. Paul Janssen suggested to his father the ideal option for the further development of the company: to conduct research to create new medicines.

At first, Paul worked with two assistants, developing new chemical components in his father's laboratory. Success was not long in coming, already the fifth molecule, synthesized by Dr. Paul Janssen and his assistants, had unique pharmacological characteristics. The first molecule was followed by numerous other innovations in psychiatry, gastroenerology, neurology, mycology, anesthesiology, and others.

Janssen Pharmaceuticals joined the Johnson & Johnson group of companies in 2008, contributing 80 patented medicines.

"Silag" is an abbreviation of the full name "Chemical Industry Laboratory AG" (JSC "Laboratory of the chemical industry"). The company was founded in Switzerland by Bernard Joos. In 1996, Doctor of Chemistry Bernard Joos created a small research laboratory, which was later transformed into the company "Silag". By the year he discovered eight new chemical compounds and created innovative ones based on them. medicines. In 2009, Cilag became part of the Johnson & Johnson group of companies.

In 2009, Janssen Pharmaceutics and Cilag merged their divisions, and today in Europe, the Janssen-Cilag brand unites all the pharmaceutical companies of the Johnson & Johnson corporation. Janssen-Cilag is one of the most innovative pharmaceutical companies in the world, and its products are widely used in practical medicine.

The Janssen-Cilag authorship includes such drugs as haloperidol, fentanyl, risperidone, loperamide, ketoconazole and many others. Five of the company's drugs are included in the List of Vital Substances of the Russian Federation.

Links

• Janssen-Cilag
• Janssen Pharmaceutica (n.) (fr.) (eng.)

Wikimedia Foundation. 2010 .

See what "Janssen Pharmaceutica" is in other dictionaries:

Janssen Pharmaceuticals- Janssen Pharmaceutica, is a pharmaceutical company based in Beerse, in the Campine region of the province of Antwerp, Belgium. The company was established in 1953 by Dr. Paul Jansen. It was created not as a subsidiary of a chemical factory but… … Wikipedia

Janssen Pharmaceuticals- Rechtsform N.V. Gründung 1953 Sitz … Deutsch Wikipedia

Janssen Pharmaceuticals- est une compagnie pharmaceutique belge filiale de Johnson Johnson, basée à Beerse dans la province d'Anvers. La compagnie a été fondée en 1953 par le docteur Paul Janssen pour faire de la recherche pharmacologique afin de créer des médicaments… … Wikipédia en Français

Janssen (surname)- Janssen may refer to:* Zacharias Janssen (1580–1638), a Dutch spectacle maker; invented a compound microscope. * Johannes Janssen (1829–1891), German historian. * Pierre Jules César Janssen (1824–1907), French astronomer. * Saint Arnold Janssen ... ... Wikipedia

Janssen- ist der Familienname folgender Personen: Albert Edouard Janssen (1883–1966), belgischer Hochschullehrer und Politiker Albrecht Janssen (1886–1972), deutscher Schriftsteller und Übersetzer Alfred Janssen, Pseudonym des deutschen… … Deutsch Wikipedia

Janssen- may refer to: People with the surname Janssen: * Janssen (surname) Other: * Janssen (lunar crater) * Janssen Pharmaceutica, a Belgian companyee also* Jansen * Janssens ... Wikipedia

Janssen-Cilag- Janssen Cilag, a Johnson Johnson subsidiary, was founded in the early nineties by joining the marketing organizations of Cilag and Janssen Pharmaceutica. It combines the marketing activities in those countries where both companies previously… … Wikipedia

Janssen- Cette page d'homonymie répertorie les différents sujets et articles partageant un même nom. Pour l'article homophone, voir Jansen. Janssen est un patronyme d origine germanique signifiant fils de Jan. Pour consultant un article plus général ... Wikipédia en Français

Paul Jansen- Statue of Dr. Paul Janssen in Beerse, Belgium Paul Adriaan Jan, Baron Janssen (born on 12 September 1926 in Turnhout, Belgium – 11 November 2003 in Rome, Italy) was the founder of Janssen Pharmaceutica, a pharmaceutical company with over 20,000… … Wikipedia

Paul Jansen- (* 12. September 1926 in Turnhout, Belgien; † 11. November 2003 in Rom) war der Gründer des belgischen Pharmaunternehmens Janssen Pharmaceutica. Janssen Pharmaceutica gehört seit den 1950er Jahren zu Johnson Johnson. Paul Janssen wurde als Sohn… … Deutsch Wikipedia

And became part of Johnson & Johnson Pharmaceutical Research and Development (J&J R&D), now renamed Janssen Research and Development (JRD), which conducts research and development activities related to a wide range of human medical disorders, including psychiatric diseases, neurological disorders, anesthesia and analgesia, gastrointestinal disorders, fungal infections, HIV/AIDS, allergies and cancer. Janssen and Ortho-McNeil Pharmaceuticals were placed in the Ortho-McNeil-Janssen Group at Johnson & Johnson.

story

The first roots of what would become Janssen Pharmaceutica date back to 1933. In 1933, Constant Janssen, father of Paul Janssen, obtained the right to distribute Richter's pharmaceutical products, the Hungarian Pharmaceutical Company, in Belgium, the Netherlands and the Belgian Congo, from October 23, 1934 he founded N.V. Produkten Richter in Turnhout. In 1937, Constant Janssen purchased the old factory building in Statestraat 78 in Turnhout for his growing company, which he expanded during World War II into a four-story house. While still a student, Paul Janssen assisted in the development of a paracetamol (USP: acetaminophen, often referred to generically under the brand name Tylenol) called Perdolan, which would later become famous. After the war, the name of the company's products was changed to Eupharma although the name of the company Richter would remain until 1956.

Paul Janssen founded his own research laboratory in 1953 on the third floor of a building in Statestraat, so far in Richter-Eurpharma his father's company. In 1955, he and his team developed their first drug: Neomeritine (ambucetamide), an antispasmodic proved to be particularly effective in relieving menstrual pain. On April 5, 1956, the name of the company was changed to H. Laboratoria Pharmaceutica S. Janssen(named after Constant Janssen). On 27 April 1957 the company opened a new research center at Beerse, but the move to Beerse would not be completed until 1971-1972. On May 2, 1958, the research department at Beerse became independent legal entity, N.V. Research Laboratorium S. Janssen .

On October 24, 1961, the company was acquired by the American corporation Johnson & Johnson. Negotiations with Johnson & Johnson were led by Frans Van den Berg, head of the Board of Directors. On February 10, 1964, the name was changed to Janssen Pharmaceutical NV and the company's seat at Turnhout was also transferred to Beerse. The company is led by Paul Janssen, Bob Stautuisen and Frans Van Den Bergh. When pharmaceuticals also moved to Beerse in 1971-1972, the transition from Turnhout was completed. Between 1990 and 2004, Janssen Pharmaceutica expanded worldwide and the company grew to around 28,000 employees worldwide.

From the very beginning, Janssen Pharmaceutica has emphasized in its research a core activity for the development of new drugs. The research department, which was established in Beerse in 1957, has grown into a major research campus. In 1987, the Janssen Research Foundation (JRF) was founded, which conducts research into new drugs at Beerse and other laboratories around the world. Janssen Pharmaceutica has become the Flemish company with the largest research and development budget. Apart from the headquarters in Beerse with its research departments, pharmaceuticals and administrative departments, Janssen Pharmaceutica in Belgium still has offices in Berchem (Janssen-Cilag), a chemical plant in Gehl, and Janssen Biotech in Olen.

Gel's chemical plant makes the active ingredients for the company's drugs. In 1975, the first plant of the new chemical plant factory i was created in Gel, Plant II was opened in 1977, Plant III" in 1984, and Plant IV in 1995. In 1999 the rest of the chemical production in Beerse was transferred to Gel. About 80% of its active ingredients are produced here. The Gel site also produces about two-thirds of the world's chemical production pharmaceutical sector Johnson & Johnson. In 1995 Center for Molecular Design(CMD) was founded by Paul Janssen and Paul Lewi.

In 1999, Clinical Research and Preclinical Development became a global organization within Johnson & Johnson. In 2001, part of the research activities were transferred to the United States with the reorganization of research activities in Johnson & Johnson Pharmaceutical Development Research organizations (JJPRD). Scientific - research activities Janssen Research Foundation(JRF) and Johnson research institute RAO Pharmaceutical(PRI) (United States of America) were merged into a new global research organization. A new building for pharmaceutical development was completed in Beerse in 2001. In 2002, a new logistics and informatics center was opened at the new location, Beerse 2. In 2003, two new research buildings were built, in research center Discovery(DRC), and Center for Drug Safety Evaluation(DSec). Since October 27, 2004 research center Paul Janssen, for research discoveries, was opened.

In May 2016, the company launched a collaboration between MacroGenics and their preclinical cancer treatment, MGD015. The deal could net MacroGenics more than $740 million.

In September 2017, it was announced that Janssen was working with the Biomedical Advanced Research and Development Authority (Barda), a unit of the Department of Health and Human Services, to create a pandemic influenza vaccine. BARDA gives Janssen $43 million in the first year and $273 million over five years on the contract. One of the projects in the agreement is the development of a universal influenza vaccine. The goal of this vaccine will be to protect people from all or most strains of the flu.

• Imodium (loperamide)
• Haldol (haloperidol)
• Ergamisol (levamisole)
• Nizoral (ketoconazole) (Removed in 2005)
• Risperdal (risperidone)
• Sirturo (bedaquiline) is a diarylquinoline anti-TB drug discovered by Koen Andries and his team that promises a shorter and simpler treatment for multidrug-resistant tuberculosis (MDR-TB).

In China

Janssen Pharmaceutica became the first Western pharmaceutical company to set up a pharmaceutical plant in the People's Republic of China.

In 1976, Paul Janssen met Ma Haide (born George Shafiq Atem), a Lebanese-American physician who began working in China in 1933. After three days of meetings, the two agreed to bring a modernized pharmaceutical business to China. When

Janssen was formed from the merger of two pharmaceutical companies, each of which has a long tradition: it is a Belgian company Janssen Pharmaceuticals and the Swiss company "Cilag" ("Cilag").

In 1953, Janssen Pharmaceuticals was founded in Belgium by a young doctor, Paul Janssen.
In 1961, Janssen Pharmaceuticals became part of the Johnson & Johnson group of companies, contributing 80 patented drugs.
"Silag" is an abbreviation of the full name "Chemical Industry Laboratory AG" (JSC "Laboratory of the chemical industry"). The company was founded in Switzerland by Bernard Joos.
In 1933, Doctor of Chemistry Bernard Joos created a small research laboratory, which was later transformed into the Silag company.
In 1959, the Cilag company became part of the Johnson & Johnson group of companies.
In 1994, Janssen Pharmaceutics and Cilag merged their divisions, and today in Europe the Janssen brand unites all the pharmaceutical companies of the Johnson & Johnson corporation.
In 2010, more than 100 pharmaceutical companies that are part of the Johnson & Johnson Corporation united under the single Janssen brand.

Drugs and Research
Janssen is one of the most innovative pharmaceutical companies in the world and its products are widely used in medical practice. More than 50 percent of its turnover is provided by drugs introduced into circulation after 2004.

Janssen Pharmaceutica (Biers, Belgium) is the central location for integrated research, development, production of innovative medicines, office support and business development. The company has four offices in Belgium (Beers I and II, Gil and Olen) with a total of 4,200 employees.
The research center at Birsa I was included in a single global organization, together with research centers in other European countries and in the US, focusing on five major areas of research: neuroscience, infectious diseases and vaccines, oncology, immunology, and cardiovascular and metabolic diseases.
In 2010 - Subsidiaries Tibote c and Virco moved to Beers, engaged in research into infectious diseases (HIV / AIDS, tuberculosis, hepatitis C). There are two pharmaceutical factories for the production of liquid and semi-solid dosage forms, which are part of the global supply chain.
Beers II is home to financial coordination, computer support, and the Janssen Animal Health division.

Janssen-Cilag unites more than 20 thousand people from 57 countries, is one of the most important suppliers of medicines in the global pharmaceutical market, provides 41% of the annual income of Johnson & Johnson Corporation.
The company has more than 80 original developments, including haloperidol, domperidone, fentanyl, levamisole, mebendazole, cinnarizine, risperidone, loperamide, ketoconazole and many others.

"Janssen-Silag" in Russia
For 2010 - "Janssen Silag" has been operating in Russia for 20 years and is included in the "Top 5" pharmaceutical companies in Russian market.
The drugs used in oncology, gastroenterology, dermatology, nephrology and the treatment of diseases of the central nervous system are the most famous.

The company offers drugs against the most serious and common diseases in the world: cancer, HIV/AIDS and bacterial infections, schizophrenia and epilepsy, rheumatoid arthritis and psoriasis, alcoholism and depression.